UPDATE: Brean Murray Carret Raises Price Target on Inhibitex to $26

According to Brean Murray Carret, Inhibitex

target price is raised to $26. Brean Murray Carret said that Bristol-Myers Squibb and Inhibitex announced an agreement under which BMS will acquire all outstanding shares of Inhibitex for $26 per share or approximately $2.5 billion. Inhibitex closed on Friday at $9.87.